Physician profile
Marwan Saoud
NPI 1083025985
$6,688.61
in general payments reported to CMS, 2019-2025
25 companies · $1,113 in 2025
The $1,113 reported for 2025 was more than what 79% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $71.13 · 2022: $243 · 2023: $607 · 2024: $4,654 · 2025: $1,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,607 · Food and Beverage: $2,466 · Travel and Lodging: $1,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,607.37 |
| Food and Beverage | $2,465.63 |
| Travel and Lodging | $1,301.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,041.77 | 2024 | |
| Glaxosmithkline, LLC. | $654.39 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $505.42 | 2022-2025 | Fasenra, Tagrisso, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.30 | 2023-2025 | Ofev |
| Genzyme Corporation | $161.24 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $135.82 | 2022-2025 | Uptravi, Opsumit |
| Pentax of America, INC. | $106.74 | 2024 | Pentax Medical, Inspira, C2 Cryoballoon Focal Controller |
| Grifols USA, LLC | $103.65 | 2022-2025 | Prolastin-C Liquid |
| Sanofi-Aventis U.S. LLC | $89.99 | 2025 | |
| Viatris Specialty LLC | $86.14 | 2025 | Yupelri |
| Amgen INC. | $80.35 | 2022-2025 | Tezspire |
| Insmed, INC. | $75.69 | 2025 | Brinsupri, Arikayce |
| Regeneron Healthcare Solutions, INC. | $56.98 | 2024-2025 | Dupixent |
| Mylan Specialty L.P. | $50.84 | 2023-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $44.46 | 2025 | Winrevair |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $31.49 | 2025 | Zemaira |
| Pfizer INC. | $30.40 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.86 | 2022 | |
| Janssen Pharmaceuticals, INC | $25.07 | 2021 | |
| Electromed, INC. | $21.65 | 2024 | Smartvest |
| Otsuka America Pharmaceutical, INC. | $20.94 | 2023 | Rexulti |
| Verona Pharma, INC. | $19.70 | 2025 | Ohtuvayre |
| Ani Pharmaceuticals, INC. | $19.33 | 2025 | Purified Cortrophin Gel |
| Philips North America LLC | $18.01 | 2023 | |
| Inogen, INC. | $15.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marwan Saoud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.